AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27496239
Drug: Delayed oral
RxNorm normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed oral feeding (enteral feeding via jejunostomy for 5 days followed by liquid oral diet)
Trial: 22541652
Drug: Enoxaparin (low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (low-molecular-weight heparin) in intraocular infusion fluid (BSS)
Trial: 20228980
Drug: 10% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbamide peroxide gel with carbopol as the thickening agent
Trial: 20228980
Drug: 2% carbopol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% carbopol gel
Trial: 20228980
Drug: 10% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbamide peroxide paste with poloxamer as the thickening agent
Trial: 16025151
Drug: Control (hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (hospital treatment)
Trial: 10694766
Drug: Tofu diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofu diet (290 g/d)
Trial: 10694766
Drug: Lean meat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lean meat diet (150 g/d)
Trial: 9339181
Drug: OND+MPS (ondansetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OND+MPS (ondansetron 8 mg po before chemotherapy, methylprednisolone 120 mg IV before chemotherapy, followed by ondansetron 8 mg po and methylprednisolone 16 mg po on days 1-4)
Trial: 9339181
Drug: TH (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TH (conventional antiemetic treatment: benzamide plus corticosteroids with or without benzodiazepines)
Trial: 8368408
Drug: Oral postoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral postoperative corticosteroids
Trial: 22414705
Drug: Placebo (sugar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sugar pill)
Trial: 27793960
Drug: cabozantinib 60
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cabozantinib 60 mg orally once daily
Trial: 27793960
Drug: everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: everolimus 10 mg orally once daily
Trial: 25287751
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor agonist liraglutide (1.2 mg per day)
Trial: 23297810
Drug: Antidepressant cessation
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressant cessation advice given to general practitioners in cases of overtreatment.
Trial: 8927668
Drug: Continuation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation treatment with full doses of clomipramine, fluoxetine, or fluvoxamine
Trial: 8927668
Drug: Continuation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation treatment with half doses of clomipramine, fluoxetine, or fluvoxamine
Trial: 8927668
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of pharmacotherapy
Trial: 8927668
Drug: Withdrawal from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal from drug therapy (three subgroups)
Trial: 6847173
Drug: Amantadine hydrochloride
RxNorm normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine hydrochloride 300 mg/day
Trial: 6847173
Drug: Rimantadine hydrochloride
RxNorm normalized name: Rimantadine Hydrochloride
DrugBank: Rimantadine (DB00478)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rimantadine hydrochloride 300 mg/day
Trial: 2921600
Drug: Amantadine hydrochloride
RxNorm normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine hydrochloride 200 mg/day
Trial: 6847173
Drug: Rimantadine hydrochloride
RxNorm normalized name: Rimantadine Hydrochloride
DrugBank: Rimantadine (DB00478)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rimantadine hydrochloride 200 mg/day
Trial: 30871894
Drug: Daily physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily physiotherapy (mobilization, ambulation, shoulder exercises, breathing exercises)
Trial: 30311724
Drug: 1.5% olive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% olive ointment (n = 37)
Trial: 30311724
Drug: 1.5% calendula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% calendula ointment (n = 39)
Trial: 17500048
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg metformin and 2.5 mg glibenclamide per coated tablet (intervention group)
Trial: 15337557
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality therapy for ST‐PNETs
Trial: 9352964
Drug: Abciximab bolus
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab bolus and infusion
Trial: 8752612
Drug: Finasteride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5 mg daily for 6 months)
Trial: 31248841
Drug: Duloxetine (30-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (30-120 mg daily; mean 92.1 mg/day)
Trial: 31248841
Drug: Desvenlafaxine (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine (50-100 mg daily; mean 93.6 mg/day)
Trial: 15459518
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy program (Kegel exercises and interferential current) for 5 weeks, 15 sessions
Trial: 16360958
Drug: Extended-release metoprolol
RxNorm normalized name: metoprolol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release metoprolol succinate
Trial: 9606617
Drug: Flutamide 250
RxNorm normalized name: flutamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide 250 mg 3 times daily
Trial: 324257
Drug: Minoxidil (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minoxidil (average dose 19.7 mg)
Trial: 30407567
Drug: Muscimol infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Muscimol infusion
Trial: 24171300
Drug: Tacrolimus 0.03%
RxNorm normalized name: TACROLIMUS 0.03% OINT,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus 0.03% cream, applied twice a day for 4 weeks
Trial: 21737767
Drug: Bupropion 150
RxNorm normalized name: BUPROPION 150MG (SMK-C) 12HR SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion 150 mg sustained-release once daily
Trial: 19031231
Drug: Suggestion to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suggestion to become a same-sex sibling; administered 2 challenges to the temporary delusion.
Trial: 9383779
Drug: High-meat diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-meat diet (600 g)
Trial: 9383779
Drug: Low-meat diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-meat diet (40 g)
Trial: 9383779
Drug: High-meat diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-meat diet (600 g) with resistant starch (37 g)
Trial: 8936955
Drug: Recombinant Interferon-2b
RxNorm normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant Interferon-2b (IFN-2b) at a dose of 5 MU/m2 three times a week, subcutaneously for 6 months
Trial: 28679529
Drug: 50% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% of daily calories consumed at breakfast (BF group)
Trial: 28679529
Drug: 50% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% of daily calories consumed at dinner (D group)
Trial: 23787719
Drug: Individualized salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized salt and fluid restriction (1.5 L fluid and 5 g salt daily) with dietary advice and support
Trial: 16948674
Drug: Oral Health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Health Impact Profile (OHIP14)
Trial: 16948674
Drug: Oral Impacts
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Impacts on Daily Performance (OIDP)
Trial: 8215552
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 7.5% sucrose
Trial: 8215552
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of sterile water (control)
Trial: 3139429
Drug: Terfenadine (full
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (full and half dosage)
Trial: 3139429
Drug: Ranitidine (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (standard and four-fold higher dose)
Trial: 3139429
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of terfenadine and ranitidine (standard and modified dosage)
Trial: 10901337
Drug: Benzodiazepine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine therapy for GAD (diazepam and lorazepam)
Trial: 8627060
Drug: High-dose zidovudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose zidovudine (180 mg/m2/dose)
Trial: 8627060
Drug: Low-dose zidovudine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose zidovudine (90 mg/m2/dose)
Trial: 1418392
Drug: Terfenadine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (120 mg/day) and nimesulide (200 mg/day)
Trial: 1418392
Drug: Terfenadine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (120 mg/day) and placebo
Trial: 6504947
Drug: Once-daily dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosage of hydrochlorothiazide (25 mg), amiloride (2.5 mg), and timolol (10 mg)
Trial: 6504947
Drug: Twice-daily dosage
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily dosage of hydrochlorothiazide (25 mg), amiloride (2.5 mg), and timolol (10 mg)
Trial: 6504947
Drug: Both once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both once-daily and twice-daily regimens
Trial: 31798891
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure (CPAP) treatment for 12 weeks
Trial: 29432286
Drug: Extended-release carbidopa-levodopa
RxNorm normalized name: carbidopa / levodopa Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release carbidopa-levodopa (ER CD-LD)
Trial: 16208597
Drug: Valdecoxib (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib (maximum single dose: 20 mg; cumulative dose: 35 mg)
Trial: 11895538
Drug: DOXI (subgingival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOXI (subgingival application of 15% doxycycline gel)
Trial: 31658543
Drug: rhGH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH treatment (0.2 IU·kg(‐1)·d(‐1) subcutaneously for 7 days)
Trial: 31658543
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (anti-shock, anti-infection, and wound caring therapies)
Trial: 25428785
Drug: Xylitol gummy
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylitol gummy bears (7.8 g/day)
Trial: 25428785
Drug: Placebo gummy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gummy bears (inulin fiber 20 g/day)
Trial: 19563189
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Source Point and Back‐Shu Point group
Trial: 9564118
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl (mean initial dose: 69.5 micrograms fentanyl/hr; mean final dose: 167.7 micrograms fentanyl/hr)
Trial: 29652246
Drug: Prolonged-release metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release metformin (500 mg)
Trial: 26968357
Drug: Rigosertib 1800
RxNorm normalized name: Rigosertib
DrugBank: Rigosertib (DB12146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rigosertib 1800 mg per 24 h via 72-h continuous intravenous infusion administered every other week
Trial: 20022282
Drug: Estradiol antagonist
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol antagonist (4 mg/day starting on the 25th day of the previous cycle)
Trial: 20022282
Drug: Estradiol antagonist
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol antagonist
Trial: 20022282
Drug: Long agonist
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long agonist (Decapeptyl 0.1 mg starting on the 20th day of the previous cycle)
Trial: 18506026
Drug: Postoperative cisplatin-based
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative cisplatin-based chemotherapy
Trial: 18506026
Drug: Postoperative cisplatin-based
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative cisplatin-based chemotherapy with vinorelbine
Trial: 18506026
Drug: Postoperative cisplatin-based
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative cisplatin-based chemotherapy with etoposide or vinca alkaloid
Trial: 18506026
Drug: Postoperative cisplatin-based
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative cisplatin-based chemotherapy with other drugs
Trial: 12856812
Drug: Biological background
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological background knowledge
Trial: 12856812
Drug: Physiological theory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological theory of drug action curriculum
Trial: 10699223
Drug: Sleep enhancing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep enhancing medication use
Trial: 8380243
Drug: Ganciclovir (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir (6 mg/kg once per day after transplant)
Trial: 2879752
Drug: lormetazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lormetazepam (10 drops twice daily for 4 weeks)
Trial: 2879752
Drug: diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diazepam (10 drops twice daily for 4 weeks)
Trial: 20832963
Drug: Ticagrelor loading
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor loading dose
Trial: 29569476
Drug: Unilateral lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral lateral rectus resection under topical anesthesia
Trial: 22879423
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of lutein and 2 mg of zeaxanthin per day (intervention group)
Trial: 18164454
Drug: Facet injections
RxNorm normalized name: potassium acetate Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facet injections
Trial: 12745507
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch with culturally sensitive self-help quitting materials
Trial: 12745507
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch with standard self-help quitting materials
Trial: 10365496
Drug: Intravenous Sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Sedation (IVS)
Trial: 6391072
Drug: Oral propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propranolol combined with 2% pilocarpine
Trial: 6391072
Drug: 0.5% topical
RxNorm normalized name: Carac 0.5% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% topical timolol combined with 2% pilocarpine
Trial: 30344165
Drug: Paclitaxel and
RxNorm normalized name: paclitaxel and encequidar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel and fluorouracil (TF) concurrent with radiotherapy
Trial: 30344165
Drug: Paclitaxel and
RxNorm normalized name: paclitaxel and encequidar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel and cisplatin (TP) concurrent with radiotherapy
Trial: 30344165
Drug: Paclitaxel and
RxNorm normalized name: paclitaxel and encequidar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel and carboplatin (TC) concurrent with radiotherapy
Trial: 27770771
Drug: Ambrisentan (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan (5 mg once daily for 12 weeks, with dose titration to 10 mg allowed)
Trial: 23158730
Drug: 10-day sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day sequential therapy (omeprazole 0.8 - 1.0 mg/(kg·d) + amoxicillin-clavulanate 50 mg/(kg·d) for 5 days, followed by omeprazole 0.8 - 1.0 mg/(kg·d), clarithromycin 20 mg/(kg·d), and metronidazole 20 mg/(kg·d) for 5 days)
Trial: 23158730
Drug: 7-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day triple therapy (omeprazole 0.8 - 1.0 mg/(kg·d), amoxicillin-clavulanate 50 mg/(kg·d), and clarithromycin 20 mg/(kg·d) for 7 days)
Trial: 23158730
Drug: 10-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day triple therapy (omeprazole 0.8 - 1.0 mg/(kg·d), amoxicillin-clavulanate 50 mg/(kg·d), and clarithromycin 20 mg/(kg·d) for 10 days)
Trial: 23158730
Drug: 14-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day triple therapy (omeprazole 0.8 - 1.0 mg/(kg·d), amoxicillin-clavulanate 50 mg/(kg·d), and clarithromycin 20 mg/(kg·d) for 14 days)
Trial: 18496884
Drug: Cognitive Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Training (CT) - 10 sessions of 2 hours, twice weekly
Trial: 18496884
Drug: Cognitive Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Stimulation (CS) - 8 sessions of 1.5 hours, once weekly
Trial: 9787945
Drug: Neoral formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral formulation (1:1 dose-ratio conversion)
Trial: 9787945
Drug: Neoral formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral formulation (0.75 dose-ratio conversion)
Trial: 9787945
Drug: Neoral formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral formulation (1:1 and 0.75 dose-ratio conversion)
Trial: 9787945
Drug: Limited sampling
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Limited sampling strategy (three blood samples post-dosing of Neoral formulation)
Trial: 9787945
Drug: Neoral formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral formulation
Trial: 7707126
Drug: Pentostatin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentostatin (4 mg/m2 intravenously every 2 weeks)
Trial: 27650383
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of superiority and non-inferiority aims for the endpoints
Trial: 23328339
Drug: Psychoeducational treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational treatment (9 sessions of 2 hours each: 5 sessions of education about the illness + 4 sessions of autogenic relaxation)
Trial: 23328339
Drug: Psychoeducational treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational treatment
Trial: 20683595
Drug: Pamidronate 60
RxNorm normalized name: pamidronate 60 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 60 mg every 3 weeks for six cycles
Trial: 20683595
Drug: Pamidronate 90
RxNorm normalized name: pamidronate 90 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 90 mg every 3 weeks for six cycles
Trial: 10227503
Drug: Sublingual 1-hyoscyamine
RxNorm normalized name: hyoscyamine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual 1-hyoscyamine sulfate
Trial: 9772597
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine combined with cord blood infusion
Trial: 9772597
Drug: Cord blood
RxNorm normalized name: CORD BLOOD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cord blood infusion solely
Trial: 1832701
Drug: 3 capsules
RxNorm normalized name: Xymogen Medcaps T3 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules of fish oil daily for 6 months
Trial: 1832701
Drug: 6 capsules
RxNorm normalized name: TOBI Podhaler Weekly Kit, including 56 capsules (7 Blister Cards of 8 Capsules)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 capsules of fish oil daily for 6 months